AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9930389 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 7270
Study 9930389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7270
Study 8034508 — intervention group
Group type: EXPERIMENTAL
Intervention: HA vaccine
Number of subjects: 28
Study 8034508 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 28
Study 8034508 — intervention group
Group type: COMPARATOR
Intervention: Immunoglobulin alone
Number of subjects: 28
Study 3141640 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 6
Study 3141640 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion
Number of subjects: 6
Study 31974576 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 376
Study 31974576 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 376
Study 31974576 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 376
Study 31974576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 376
Study 31974576 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 376
Study 31974576 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 376
Study 31974576 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 376
Study 30573030 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAD and diabetes
Number of subjects: 13885
Study 30573030 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 13885
Study 30573030 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 1% increase in HbA1c
Number of subjects: 13885
Study 27106880 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month physical activity intervention
Number of subjects: 211
Study 27106880 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 211
Study 26253219 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (2-hour sessions once a week for 6 weeks)
Number of subjects: 430
Study 24283773 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg per week for 12 weeks
Number of subjects: 58
Study 24283773 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 58
Study 21348912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with dutasteride (0.5 mg) and tamsulosin (0.4 mg)
Number of subjects: 4844
Study 19056900 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU cholecalciferol twice a week
Number of subjects: 445
Study 19056900 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU once a week plus placebo
Number of subjects: 445
Study 19056900 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice a week
Number of subjects: 445
Study 19056900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups receiving cholecalciferol
Number of subjects: 445
Study 19056900 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 445
Study 16563974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 67
Study 16563974 — intervention group
Group type: COMPARATOR
Intervention: microemulsion cyclosporine (mCyA)
Number of subjects: 67
Study 12910217 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic prosthetic hernia repair
Number of subjects: 0
Study 12910217 — intervention group
Group type: COMPARATOR
Intervention: Open prosthetic hernia repair
Number of subjects: 0
Study 10228257 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 220
Study 10228257 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 220
Study 8934457 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory for conversation
Number of subjects: 0
Study 1655299 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium 1 mg.kg‐1 (single-dose)
Number of subjects: 48
Study 1655299 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium 0.75 mg.kg‐1 (single-dose)
Number of subjects: 48
Study 1655299 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium 0.25 mg.kg‐1 followed by 0.75 mg.kg‐1 (divided-dose)
Number of subjects: 48
Study 1655299 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium 0.25 mg.kg‐1 followed by 0.50 mg.kg‐1 (divided-dose)
Number of subjects: 48
Study 1655299 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium (divided doses)
Number of subjects: 48
Study 6751003 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment (25 mg hydrochlorothiazide and 50 mg triamterene)
Number of subjects: 331
Study 6751003 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 331
Study 31690945 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound thalamotomy (FUS-T) in the postpivotal group
Number of subjects: 179
Study 31690945 — intervention group
Group type: COMPARATOR
Intervention: Focused ultrasound thalamotomy (FUS-T)
Number of subjects: 179
Study 30711665 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad training using a web-based brain game suite, Brain HQ
Number of subjects: 230
Study 30711665 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad training using a strategy video game, Rise of Nations
Number of subjects: 230
Study 30711665 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed training for Instrumental Activities of Daily Living (IADL) using web-based programs for driving and fraud avoidance
Number of subjects: 230
Study 30711665 — intervention group
Group type: COMPARATOR
Intervention: Active control condition of puzzle solving
Number of subjects: 230
Study 27911341 — intervention group
Group type: EXPERIMENTAL
Intervention: MAO-B inhibitors
Number of subjects: 1616
Study 27460618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training & Exercise (CT&E)
Number of subjects: 16
Study 27460618 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Training (CT)
Number of subjects: 16
Study 23730719 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
Number of subjects: 341
Study 23730719 — intervention group
Group type: COMPARATOR
Intervention: Nontargeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
Number of subjects: 341
Study 23730719 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Only
Number of subjects: 341
Study 21941012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g of NaHCO3 per kilogram body mass)
Number of subjects: 0
Study 21941012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.15 g of corn flour per kilogram body mass)
Number of subjects: 0
Study 19685757 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection 0.6 mL x kg(‐1) added to physiological saline 250 mL after anaesthesia before CPB
Number of subjects: 30
Study 19685757 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline 250 mL
Number of subjects: 30
Study 17854336 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental provision of alcohol and home alcohol availability
Number of subjects: 1388
Study 17854336 — intervention group
Group type: EXPERIMENTAL
Intervention: Student report of receiving alcohol from their parent or taking it from home during their last drinking occasion
Number of subjects: 1388
Study 15109974 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lidocaine
Number of subjects: 10
Study 15109974 — intervention group
Group type: COMPARATOR
Intervention: Phasic mechanical stimulation
Number of subjects: 10
Study 12090798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium
Number of subjects: 17
Study 12090798 — intervention group
Group type: EXPERIMENTAL
Intervention: Manorapid
Number of subjects: 17
Study 12090798 — intervention group
Group type: COMPARATOR
Intervention: Desderman, AHD 2000, Mucasept A, Spitacid
Number of subjects: 17
Study 10555740 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear Compatibles lenses
Number of subjects: 10
Study 10555740 — intervention group
Group type: COMPARATOR
Intervention: Acuvue lenses
Number of subjects: 10
Study 10555740 — intervention group
Group type: COMPARATOR
Intervention: Soflens 66 lenses
Number of subjects: 10
Study 8526620 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II heparin coat
Number of subjects: 40
Study 8526620 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmeda Biological Active Surface
Number of subjects: 40
Study 8526620 — intervention group
Group type: COMPARATOR
Intervention: Uncoated equipment (Control)
Number of subjects: 40
Study 2405964 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 62
Study 2405964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 6154110 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon administration
Number of subjects: 41
Study 6154110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 41
Study 29656495 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable membrane (RES)
Number of subjects: 23
Study 29656495 — intervention group
Group type: COMPARATOR
Intervention: Titanium-reinforced nonresorbable membrane (N-RES)
Number of subjects: 23
Study 27362458 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied after eccentric exercise
Number of subjects: 10
Study 27362458 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PR) after eccentric exercise
Number of subjects: 10
Study 24394548 — intervention group
Group type: EXPERIMENTAL
Intervention: FAN intervention
Number of subjects: 0
Study 22992861 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A performed one meniscal repair each month
Number of subjects: 19
Study 22992861 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B performed one meniscal repair at three months
Number of subjects: 19
Study 22992861 — intervention group
Group type: COMPARATOR
Intervention: Group C performed no repairs during this interim phase
Number of subjects: 19
Study 20535962 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine with high-dose IL-2
Number of subjects: 0
Study 20535962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC) vaccine of prostate-acid protein plus GM-CSF
Number of subjects: 0
Study 20535962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20535962 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 vaccine for non-small cell lung cancer
Number of subjects: 0
Study 18179915 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized internal thoracic artery harvesting (Group 1)
Number of subjects: 24
Study 18179915 — intervention group
Group type: COMPARATOR
Intervention: Pedicled internal thoracic artery harvesting (Group 2)
Number of subjects: 24
Study 16393758 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic dementia (SDL)
Number of subjects: 3
Study 16393758 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's disease (AD)
Number of subjects: 3
Study 16393758 — intervention group
Group type: COMPARATOR
Intervention: Semantic dementia (SDR)
Number of subjects: 3
Study 16393758 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic dementia (SD)
Number of subjects: 3
Study 16393758 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal episodic memory tests
Number of subjects: 3
Study 16393758 — intervention group
Group type: COMPARATOR
Intervention: Visual memory tests
Number of subjects: 3
Study 12669250 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemotherapy (cisplatinum 30 mg/m2 days 1-3, DTIC 250 mg/m2 days 1-3 i.v., Interferon-alpha2b 10 MIU s.c. 3 days a week, on a 28-day cycle)
Number of subjects: 10
Study 12669250 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (14 patients total)
Number of subjects: 10
Study 12669250 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemotherapy (cisplatinum, DTIC, Interferon-alpha2b)
Number of subjects: 10
Study 10839336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 55
Study 10839336 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral ECT (RUL)
Number of subjects: 55
Study 10839336 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 55
Study 10839336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients post-ECT
Number of subjects: 55
Study 8979185 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen umbilical catheter
Number of subjects: 0
Study 8979185 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen umbilical catheter
Number of subjects: 0
Study 8979185 — intervention group
Group type: COMPARATOR
Intervention: No umbilical catheter; peripheral intravenous lines only (control group)
Number of subjects: 0
Study 1485658 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine
Number of subjects: 12
Study 1485658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6427714 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms mestranol plus 0.5 mg ethynodiol diacetate (100 M + 0.5 ED)
Number of subjects: 169
Study 6427714 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms mestranol plus 1.0 mg ethynodiol diacetate (100 M + 1.0 ED)
Number of subjects: 169
Study 6427714 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms ethinyl estradiol plus 1.0 mg ethynodiol diacetate (50 EE + 1.0 ED)
Number of subjects: 169
Study 6427714 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol plus 2.0 mg ethynodiol diacetate (30 EE + 2.0 ED)
Number of subjects: 169
Study 6427714 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol plus 0.15 mg levonorgestrel (30 EE + 0.15 NG)
Number of subjects: 169
Study 6427714 — intervention group
Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 169
Study 6427714 — intervention group
Group type: COMPARATOR
Intervention: Comparative analysis between 50 EE + 1.0 ED and 100 M + 1.0 ED
Number of subjects: 169
Study 3532141 — intervention group
Group type: EXPERIMENTAL
Intervention: Short leg casting
Number of subjects: 16
Study 3532141 — intervention group
Group type: COMPARATOR
Intervention: No short leg casting (uncasted group)
Number of subjects: 16
Study 30998422 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (2% w/v) with zinc acetate (1.2% w/v) topical gel
Number of subjects: 102
Study 30998422 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (2% w/v) gel alone
Number of subjects: 102
Study 29534444 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate + Protein (CP) during the run (CPDuring)
Number of subjects: 32
Study 29534444 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate + Protein (CP) immediately following exercise (CPPost)
Number of subjects: 32
Study 29534444 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) during the run (CHODuring)
Number of subjects: 32
Study 29534444 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) immediately following exercise (CHOPost)
Number of subjects: 32
Study 27549313 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia with sevoflurane for 30 min before removal of the flap and throughout the surgery (BAL group)
Number of subjects: 54
Study 24411797 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug positive (marijuana and other drugs) among sober drivers
Number of subjects: 0
Study 24411797 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug positive (marijuana and other drugs) among drinking drivers
Number of subjects: 0
Study 24411797 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drugs (excluding marijuana)
Number of subjects: 0
Study 24411797 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 22744901 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assisted vasovasostomy and vasoepididymostomy
Number of subjects: 0
Study 22744901 — intervention group
Group type: COMPARATOR
Intervention: Standard microsurgical vasovasostomy (MVV) and vasoepididymostomy (MVE)
Number of subjects: 0
Study 19967408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual constructive communication
Number of subjects: 75
Study 19967408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual avoidance
Number of subjects: 75
Study 19967408 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient demand-partner withdraw communication
Number of subjects: 75
Study 19967408 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐disclosure
Number of subjects: 75
Study 19967408 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding back
Number of subjects: 75
Study 19967408 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner demand-patient withdraw communication
Number of subjects: 75
Study 18767584 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion with thunder-fire herbal moxa stick and massage of acupoints and lacrimal gland around the eye
Number of subjects: 70
Study 18767584 — intervention group
Group type: COMPARATOR
Intervention: Local dripping Leiran Diyanye
Number of subjects: 70
Study 18767584 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion with thunder-fire herbal moxa stick
Number of subjects: 70
Study 15869543 — intervention group
Group type: EXPERIMENTAL
Intervention: Myobloc (botulinum toxin type B) 2500 U (0.5 ml) per axilla
Number of subjects: 20
Study 15869543 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml vehicle (placebo)
Number of subjects: 20
Study 12672711 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (150 micro g of selenium, 2000 IU of retinol, 120 mg of ascorbic acid, 30 IU of alpha‐tocopherol) with taper training (TT)
Number of subjects: 16
Study 12672711 — intervention group
Group type: COMPARATOR
Intervention: Taper training (TT)
Number of subjects: 16
Study 10744143 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil treatment
Number of subjects: 203
Study 8808777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dipyridamole (150 mg) and aspirin (100 mg) pellet formulation
Number of subjects: 12
Study 8808777 — intervention group
Group type: COMPARATOR
Intervention: Conventional products (dipyridamole and aspirin) given twice daily
Number of subjects: 12
Study 1422712 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour-coded duplex ultrasonography
Number of subjects: 73
Study 2413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg i.v.)
Number of subjects: 12
Study 2413307 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.4 mg i.v.)
Number of subjects: 12
Study 2413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg i.v.) plus Naloxone (0.4 mg i.v.)
Number of subjects: 12
Study 2413307 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.4, 2.0, and 8.0 mg i.v.)
Number of subjects: 12
Study 30452784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulacimstat 5 mg twice daily (n=9)
Number of subjects: 39
Study 30452784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulacimstat 10 mg twice daily (n=9)
Number of subjects: 39
Study 30452784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulacimstat 25 mg twice daily (n=10)
Number of subjects: 39
Study 30452784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulacimstat 50 mg once daily (n=9)
Number of subjects: 39
Study 30452784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 39
Study 29635717 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic screening for esophageal cancer
Number of subjects: 18316
Study 29635717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endoscopic screening)
Number of subjects: 18316
Study 27717303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg per day on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day)
Number of subjects: 668
Study 27717303 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole (2.5 mg per day)
Number of subjects: 668
Study 27717303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 668
Study 27717303 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 668
Study 25001077 — intervention group
Group type: EXPERIMENTAL
Intervention: Your Health intervention (consultation with the school nurse)
Number of subjects: 418
Study 22706884 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cancer survivors (LTCSs)
Number of subjects: 2008
Study 22706884 — intervention group
Group type: COMPARATOR
Intervention: Cancer-free control group
Number of subjects: 2008
Study 20559229 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cycloferon liniment in comprehensive treatment of parodontitis
Number of subjects: 80
Study 20559229 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cycloferon liniment
Number of subjects: 80
Study 17589833 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg
Number of subjects: 624
Study 17589833 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 225 mg
Number of subjects: 624
Study 17589833 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg
Number of subjects: 624
Study 17589833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 15674514 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block
Number of subjects: 100
Study 15674514 — intervention group
Group type: COMPARATOR
Intervention: Caudal block
Number of subjects: 100
Study 11880017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg
Number of subjects: 120
Study 11880017 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 120
Study 11880017 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study 11139092 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 11139092 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 11139092 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 0
Study 11139092 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0